Guidance for Supernus Pharm (SUPN)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2026 | N/A | N/A | $840.00M – 870.00M | $861.20M | = Maintained | Details |
| 2025 | N/A | N/A | $670.00M – 700.00M | $636.40M | = Maintained | Details |
| 2024 | N/A | N/A | $630.00M – 650.00M | $619.50M | = Maintained | Details |
| 2024 | N/A | N/A | $580.00M – 620.00M | $601.46M | = Maintained | Details |
| Q1 2024 | N/A | N/A | $580.00M – 620.00M | $622.50M | = Maintained | Details |
| 2023 | N/A | N/A | $640.00M – 680.00M | $683.00M | = Maintained | Details |
| 2022 | N/A | N/A | $640.00M – 680.00M | N/A | = Maintained | Details |
| 2022 | N/A | N/A | $640.00M – 680.00M | $707.32M | = Maintained | Details |
| 2021 | N/A | N/A | $550.00M – 580.00M | $558.00M | = Maintained | Details |
| 2021 | N/A | N/A | $550.00M – 580.00M | $569.54M | = Maintained | Details |
| 2021 | N/A | N/A | $550.00M – 580.00M | $581.47M | = Maintained | Details |
| 2020 | N/A | N/A | $500.00M – 525.00M | $486.54M | = Maintained | Details |
| 2020 | N/A | N/A | $360.00M – 390.00M | $407.70M | = Maintained | Details |
| 2019 | N/A | N/A | $390.00M – 395.00M | $413.08M | = Maintained | Details |
| 2019 | N/A | N/A | $400.00M – 410.00M | $439.02M | = Maintained | Details |
| 2017 | N/A | N/A | $388.00M – 395.00M | $398.70M |  Lowered |
Details |
| 2017 | N/A | N/A | $385.00M – 400.00M | $403.91M | = Maintained | Details |
| 2017 | N/A | $1.86 | $375.00M – 400.00M | $398.50M | = Maintained | Details |
| Q1 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| 2016 | N/A | N/A | $200.00M – 210.00M | $207.00M | = Maintained | Details |
